A Phase III Randomized Placebo-Controlled Study of Pembrolizumab (MK-3475 NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA Stage IVB or Recurrent Endometrial Cancer



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.